5:59 PM
 | 
Jan 14, 2013
 |  BC Extra  |  Company News

FDA to discuss Cangene's botulism antitoxin

FDA's Blood Products Advisory Committee will meet on Feb. 12 to discuss a BLA from Cangene Corp. (TSX:CNJ) for botulism antitoxin heptavalent (BAT) to treat botulism. The company...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >